Last updated: February 27, 2026
What is NDC 00143-9250?
NDC 00143-9250 refers to Eliquis (apixaban), an anticoagulant developed by Bristol-Myers Squibb and Pfizer. It is used to prevent stroke in atrial fibrillation, treat deep vein thrombosis, and pulmonary embolism.
Market Overview
Market Size (2022-2027)
The global anticoagulant market was valued at approximately $8.2 billion in 2022. Expected compound annual growth rate (CAGR) is 7.3%, projecting a market size of $13.7 billion by 2027. Factors driving growth include increasing prevalence of atrial fibrillation, rising incidence of venous thromboembolism (VTE), and expanding use in surgical settings.
Competitive Landscape
Key competitors include:
- Eliquis (apixaban)
- Xarelto (rivaroxaban)
- Dabigatran (Pradaxa)
- Betrixaban (Bevyxxa)
Eliquis maintains a leading market share, approx. 30% globally as of 2022, due to superior safety profile and efficacy.
Market Share Trends
| Year |
Eliquis |
Xarelto |
Dabigatran |
Betrixaban |
| 2020 |
29% |
40% |
15% |
4% |
| 2022 |
30% |
38% |
14% |
4% |
| 2024 (projected) |
31% |
36% |
13% |
4% |
Source: EvaluatePharma, 2023.
Price Analysis
Current Pricing (2023)
| Region |
Estimated Wholesale Acquisition Cost (WAC) |
30-day Patient Cost |
Average List Price |
| US |
$511 per month |
$511 |
$585 |
| Europe |
€380 ($415) monthly |
€380 |
€440 |
| Japan |
¥45,000 ($410) monthly |
¥45,000 |
¥49,000 |
Pricing Trends (2018-2023)
Eliquis pricing has remained stable in key markets due to patent protection and market dominance. No significant discounts or biosimilar competition exists currently. U.S. reimbursement has maintained high coverage, supporting stable margins.
Patent Status
Patent protection extends until 2026 in the U.S. and until 2028 in the EU. Patent cliff is expected to generate biosimilar competition post-2026, potentially impacting the price.
Regulatory and Commercial Considerations
- Patent expiration in the U.S. in 2026 may lead to biosimilar entrants.
- FDA approval for additional indications, including orthopedic surgeries, could increase market penetration.
- Pricing pressure from biosimilars and payer negotiations could reduce pricing margins.
Price Projections (2024-2028)
| Year |
Projected Average Price |
Key Factors |
| 2024 |
$560 |
Stable patent protection |
| 2025 |
$550 |
Slight reimbursement pressure from payers |
| 2026 |
$500 |
Patent expiration, biosimilar competition begins |
| 2027 |
$470 |
Biosimilars gain market share, increased competition |
| 2028 |
$430 |
Multiple biosimilar entrants, reduced brand dominance |
Note: These projections assume no significant regulatory changes or pricing reforms.
Key Drivers and Risks
Drivers
- Growing prevalence of atrial fibrillation
- Expanding indications
- High brand loyalty and clinical preference
- Strong reimbursement support
Risks
- Patent expiration leading to biosimilar entry
- Price erosion due to biosimilar competition
- Regulatory delays for new indications
- Market saturation in developed countries
Key Takeaways
- Eliquis (NDC 00143-9250) dominates the anticoagulant market with approximately 30% share.
- The market is projected to grow at a CAGR of 7.3% until 2027.
- Current prices remain stable in the U.S. and Europe, supported by patent protections.
- Biosimilar competition after 2026 likely to decrease prices, potentially by 25-35% over two years.
- Market expansion hinges on approval of additional indications and geographic expansion.
FAQs
1. When will biosimilar competition for Eliquis begin?
Biosimilar products are expected to enter the U.S. market after patent expiration, targeted for 2026.
2. How will biosimilars impact pricing?
Introduction of biosimilars typically results in a 25-35% price reduction within two years.
3. Are there regulatory barriers to Eliquis expansion?
Yes. New indications require FDA or EMA approval, which can take 1-3 years.
4. What markets offer the highest growth potential?
Emerging markets in Asia, Latin America, and certain Middle Eastern countries are projected to see increased demand.
5. How does Eliquis compare to rivaroxaban in market performance?
Eliquis has a higher market share and better safety profile, but rivaroxaban offers lower pricing in some regions, creating price competition.
References
- EvaluatePharma. (2023). Pharmaceutical Market Data.
- IQVIA. (2023). Global Market Trends for Anticoagulants.
- U.S. Food and Drug Administration. (2023). Drug Approvals and Patent Expiry Data.
- European Medicines Agency. (2023). Regulatory Status of Eliquis.
